Pharmaceutical companies might experience spontaneous fiscal arousal upon reading a new medical study about drugs that may cause spontaneous orgasms. The study is:
“Drug-Associated Spontaneous Orgasm: A Case Report and Systematic Review of Literature,” Wei-Hsi Chen, Yuan-Hsiang Chu, and Kuo-Yen Chen, Clinical Neuropharmacology, epub 2017. The authors, at Shu-Te University and Chang Gung University, Taiwan, explain:
We report a male patient of repetitive spontaneous orgasm under trazodone treatment and systematically review the literature on drug-associated spontaneous orgasm (DASO)…. A total of 25 patients (18 women and 7 men), including our reported case, experienced 27 DASO events…. A reduction of dose or discontinuation of the offending drug usually abolished DASO….
Sex and age seem to have no influence on occurrence of DASO events….
Index drugs induced SPONO [spontaneous orgasm] but did not change the quality of the classical orgasm….
There is an equal likelihood that SPONO will occur within 7 days or between 8 days and 1 month after drug use regardless of drug type. An immediate reaction following drug administration is rare.
Smart investors can be on the listen for mention of the suddenly-chic phrases “DASO” and “SPONO”, at cocktail parties where pharma executives roam.
Marc Gozlan wrote an appreciation of this new research, in the Réalités Biomédicales blog in Le Monde: “Ces médicaments qui déclenchent des orgasmes spontanés.”